Stentys to Acquire Cappella Peel Away Stent Delivery Technology

June 4, 2014—Stentys announced the signing of an acquisition agreement of Cappella Peel Away Inc. and its assets relating to a novel stent delivery system. The transaction, which is the company’s first strategic acquisition, is subject to closing conditions. The catheter technology will enable the implantation of the Stentys Self-Apposing stent in the same manner as a conventional balloon-expandable stent. 

Stentys will incorporate the technology into its next-generation delivery system for the company’s line of bare-metal and drug-eluting stents and expects to start commercializing these in 2015.

The Cappella Peel Away technology, with which the cardiologist inflates a small balloon that splits open the stent-containing sheath to release the stent in the vessel at the desired location, has been used as part of Cappella’s Sideguard coronary bifurcation stent. The Sideguard device has received European CE Mark approval and has been clinically validated by an extensive number of Sideguard stent implants, noted Stentys.

According to Stentys, the Cappella Peel Away Inc. assets consist of a license agreement on patents related to the novel peel-away sheath technology for a stent delivery system, technical specifications and drawings, clinical and regulatory documentation, and equipment from Cappella Inc. The latter will retain the rights to the peel-away sheath technology for its Sideguard coronary bifurcation stent and for other potential applications including peripheral vascular indications.

The Stentys Self-Apposing stent has been marketed in Europe since receiving CE Mark approval in 2010. The Stentys sirolimus-eluting stent is expected to receive CE Mark approval during the second half of 2014, advised the company.